The Library at Children's National
Sometime in the mid-1990s — the exact night is lost, as most pivotal nights are — a parent sat in the basement library of Children's National Medical Center in Washington, D.C., reading articles about a disease she could barely pronounce. Upstairs, in the intensive care ward, her youngest daughter slept fitfully, her oxygen-starved blood pressing against narrowing arteries with the urgency of water forced through a kinked hose. The parent had no medical training. Her expertise, such as it was, lay in satellite communications — in the physics of signals beamed from geostationary orbit, in the regulatory arcana of the Federal Communications Commission, in the strange alchemy of turning radio frequencies into billion-dollar businesses. She had founded Sirius Satellite Radio. She held patents on aspects of satellite-to-car broadcasting. She understood the inverse relationship between signal power and antenna size the way a pianist understands scales. None of this, it must be said, was useful in a pediatric ICU.
The doctors at Children's National had been direct. The disease was called pulmonary arterial hypertension. It was progressive, essentially untreatable, and almost uniformly fatal within two to three years of diagnosis. The head of pediatric cardiology had seen only two or three other children with the condition. They had all died. The best hope was a lung transplant — nearly unheard-of in a child that small — and even that merely traded one death sentence for another, half of lung transplant recipients dying within five years from chronic rejection. There was nothing else to discuss.
Martine Rothblatt did not accept this. She went to the library. She read. When she encountered words she didn't understand — and she encountered them constantly, long chemical chains and anatomical terms that bore no resemblance to anything she had learned at UCLA Law or in the engineering bays of Hughes Aircraft — she went backwards through the pedagogical ladder: from peer-reviewed journal to college anatomy textbook to high school biology primer, then back up again. She followed every footnote, applied the legal research technique of Shepardizing — the exhaustive practice of tracing every citation in a court opinion to its source, then tracing the sources' citations, spiraling downward until the references loop back on themselves — to medical literature. When her daughter Jenesis was well enough to leave the ICU for the regular ward, Rothblatt would bring her down to the library, where the child sat beside her mother filing articles, the two of them working through the footnotes together. A father becoming a woman and a daughter with a fatal disease, sitting side by side in the nation's hospital libraries, reading about prostaglandin analogs.
This is, depending on your angle of approach, either the most improbable origin story in American business or the most inevitable.
By the Numbers
The Rothblatt Universe
$14.7BUnited Therapeutics market capitalization (2024)
$2.1BAnnual revenue from five FDA-approved PAH drugs
30M+SiriusXM subscribers worldwide
50,000People living with PAH today (vs. 2,000 at time of Jenesis's diagnosis)
$25,000Upfront cost to license treprostinil from Glaxo Wellcome
$1B+Royalties subsequently paid to Glaxo on that molecule
9U.S. patents as inventor or co-inventor
A Dentist's Son in San Diego
She was born Martin Rothblatt on October 10, 1954, in Chicago, the first child of Harold Rothblatt, a dentist, and Rosa Lee, a speech therapist. The family was observant Jewish, which mattered more than you might think — the weekly discipline of Sabbath dinner, the sense of chosenness rubbing against marginality, would later inform rituals Rothblatt designed for her own family and, eventually, for an entire transhumanist religion. They relocated to the working-class suburbs of San Diego, where the Rothblatts were the only Jewish family in a mostly Hispanic neighborhood. The boy grew up obsessed with difference, seeking out families unlike his own.
When Martin was five, Harold was badly injured in a car accident and appeared destined for permanent paralysis. He closed his practice, declared bankruptcy, and the family's secure world dissolved. Then an experimental surgery at the Mayo Clinic repaired the damage to his spine, and Harold Rothblatt walked again, resuming his practice, his life snapping back into place as though the catastrophe had been merely provisional. It was the kind of lesson a child absorbs at the cellular level: that human ingenuity can reverse even the most final-seeming verdicts. That the experts who said this cannot be undone were sometimes wrong. Decades later, Martine would invoke her father's story when explaining why she believed she could save her daughter, cure a disease she couldn't pronounce, build lungs from tobacco plants, or fly an electric helicopter. The template was always the same. Authority says impossible. The body — the technology, the molecule, the frequency — says otherwise.
Rosa Lee, for her part, remembers the child she held in the living room a few days after birth: "Menashe, honey — that's his Hebrew name — I don't know what it is, but there's something special about you. You will make a difference in this world." An almost comically prophetic maternal instinct, except that the child in question would go on to create satellite radio, found a multi-billion-dollar pharmaceutical company, undergo sex-reassignment surgery, design the world's first electric helicopter, build a sentient robot modeled on her wife, construct the world's largest net-zero office building, and pioneer the transplantation of genetically modified pig organs into humans. At some point, maternal instinct stops being prophecy and starts being understatement.
Martin was a fanatical reader — Exodus by Leon Uris, anything by Isaac Asimov, and especially Black Like Me by John Howard Griffin, that strange, searing account of a white journalist who darkened his skin to experience the Jim Crow South. The books about outsiders and boundary-crossers were the ones that stuck. He was also an unmotivated student, which is perhaps the most surprising detail in the entire biography, given what came later. He dropped out of UCLA after his freshman year, wanting to see the world, and with a few hundred dollars in his pocket made his way to the Seychelles, a scattering of islands in the Indian Ocean that he'd read were like a paradise. The Seychelles disappointed. Cockroaches. Heat. Not much to do.
But at the top of the mountain on the main island, there was a NASA satellite tracking station.
The Lightning Bolt in the Indian Ocean
It was 1974. Rothblatt was a grungy nineteen-year-old hitchhiker, and the engineers inside the tracking station were kind and patient with him, explaining how their antennas communicated with satellites in all different orbits — some circling Earth, others beaming data from as far away as Jupiter. Rothblatt asked whether it would be possible for someone to put a satellite up there and have it broadcast information back to the entire planet. The engineers said: if you made a powerful enough satellite, the receiving equipment on Earth could be so small you could hold it in the palm of your hand.
"I could have kissed the guy," Rothblatt later recalled. "I just said, 'Wow, that's the purpose of my life.'"
She describes this feeling — and it recurs throughout her career, a kind of repeating motif — as "a lightning bolt to your soul." Not metaphorical. A physiological event, visceral and clarifying, that rearranges priorities and collapses the distance between idea and identity. Rothblatt experienced it at the NASA station. She experienced it again years later, reading the Tesla manual and realizing its 750-kilowatt output matched the horsepower of her Bell 206 JetRanger helicopter. She experienced it reading a Scientific American cover story about using electronics to cure diseases, recognizing the possibility of merging her satellite expertise with her medical work. Each time, the pattern was identical: a piece of technical information, encountered in an ordinary setting, that suddenly illuminated an entire architecture of possibility.
She made a beeline back to UCLA. Changed her major to communication studies. Wrote an undergraduate thesis on direct broadcast satellites under the guidance of Andrea Rich, a communications professor who, rather than laughing off the student's paper on interstellar communications — the possibility of using the Earth's solar orbit as a baseline for a giant transmitting antenna — complimented the ambition and pointed out ways to improve it. Rothblatt enrolled in UCLA's joint JD/MBA program, publishing five articles on satellite communications law while simultaneously earning both degrees. She graduated summa cum laude, Order of the Coif. The grungy dropout had become a polymath with a legal, business, and technical toolkit, and a burning conviction that the satellite was the most important technology on Earth.
The Corridors of Indifference
The phrase Rothblatt uses most often to describe her strategic philosophy is borrowed from no one in particular: "Identify the corridors of indifference and run like hell down them." In practice, this means finding problems so neglected, markets so small, or technologies so dismissed that no one with conventional ambition would bother. It means, in the language of General Electric's Jack Welch — whom Rothblatt studied at UCLA Anderson — that if you can't be number one or number two in a market, don't bother. But Rothblatt inverts the principle: choose markets so narrow that being number one is achievable simply because everyone else has walked away.
Her first corridor was satellite navigation. In 1982, Gerard K. O'Neill — the Princeton physicist whose book
The High Frontier had inspired a generation of space enthusiasts, including a young
Jeff Bezos — hired Rothblatt to handle business and regulatory matters for his newly invented satellite navigation technology, GeoStar. Rothblatt launched the system in 1986; it continues to operate today, providing service to certain government agencies. She was, at this point, a telecommunications lawyer who had become a satellite entrepreneur, which was itself an unusual transition, but nothing compared to what was coming.
The corridor that made her famous was radio. In the mid-1980s, satellite dishes were enormous — "the state flower of West Virginia," she jokes — because the signals from space were weak. But Rothblatt understood the physics: dish size was inversely proportional to signal power. Rockets were getting larger. Satellites could carry more powerful transmitters. Folding aperture antennas could concentrate the beam on smaller portions of the Earth's surface — just the United States, say, rather than the entire hemisphere visible from geostationary orbit. If the signal were powerful enough, the receiving dish could shrink to the size of a few fingers, flat enough to mount on a car roof. You could listen to satellite radio while driving anywhere in the country.
She went first to the existing broadcasters — ABC Radio, CBS Radio, Infinity Radio — certain they would be excited. Every single one told her the idea was ridiculous. Their engineers insisted a satellite-to-car signal was physically impossible. The FCC, they argued, would never approve a single company controlling a hundred channels in every nook and cranny of the nation; it contravened the Communications Act. And even if you overcame those obstacles, who would listen on day one? No listeners meant no advertisers. When Rothblatt suggested a subscription model — no ads, people would pay — they laughed. "Nobody's gonna pay for radio."
I said, 'But they pay for TV.' They said, 'That's different.' So I could not get the existing industry to agree to do this.
She found the frequencies herself — bands ideal for passing through the atmosphere without attenuation — and persuaded the FCC to reallocate them from electronic newsgathering trucks to satellite radio. She raised capital on Wall Street, protected by patents filed with the USPTO and a semi-exclusive FCC license. Sirius Satellite Radio launched in 1990. It would eventually merge with its competitor XM and grow into SiriusXM, the largest audio entertainment company in North America, valued at approximately $19 billion, with more than 30 million subscribers. Howard Stern, the network's marquee talent, once told Rothblatt he wouldn't be where he was without her. She liked it, she said, when he called her "Martin Luther Queen."
The pattern was set. Rothblatt would identify a technology that physics said was possible but that convention said was absurd. She would master the regulatory environment, file patents, and raise capital. She would endure years of being told — not once, not twice, but by every expert and institution she consulted — that the thing could not be done. And then she would do it.
The Transition
Around the time Sirius went public in 1993, Rothblatt sat down with Bina and their children and said something that had been true for decades but had never been spoken aloud: that she had always felt her soul was female, but had been afraid to express it outwardly. "I always kept it bottled up and just showed my male side," she later explained.
The family's responses have become a kind of foundational text in the Rothblatt mythology. Bina said: "I love your soul, and whether the outside is 'Martin' or 'Martine,' it doesn't matter to me because I love your soul." Their son asked: "If you become a woman, will you still be my father?" Martine said yes. Their youngest daughter — five years old — told people: "I love my dad, and she loves me." The child, Rothblatt observed, "had no problem with gender blending whatsoever."
Bina Aspen, who had married Martin in 1982 after they met at a networking event for minorities in business during Rothblatt's MBA years, would later describe herself not as straight or gay but as "Martine-sexual" — as in the only person she wanted to have sex with was Martine. They are still married, more than forty years on. At home, the children call her "Dad." To her four grandchildren she is "Grand Martine."
Rothblatt underwent sex-reassignment surgery in 1994. In the years immediately following, her presentation was more conventionally feminine — lipstick, long curly hair worn loose. But over time she developed what can only be described as her own unisexual style: cargo pants, a T-shirt, a floppy button-down thrown on top, no makeup, no jewelry. She inhabits her muted clothing in the youthful, offhand way of the tech elite. A person for whom gender mattered enough to undergo radical surgery, but not enough to care which pronoun strangers used. "Martine" was what she preferred.
In 1995, just after her transition, she published
The Apartheid of Sex: A Manifesto on the Freedom of Gender, a slim book arguing that the binary classification of humans into male and female was as arbitrary and oppressive as racial apartheid. The Kirkus review called it "overly optimistic," which may be the most consistently applicable critique of everything Rothblatt has ever done. Her 2011 revision,
From Transgender to Transhuman, expanded the argument: if the boundary between male and female was permeable, why not the boundary between human and machine, between mortal and immortal, between carbon and silicon?
I can't claim that what I have achieved is equivalent to what a woman has achieved. For the first half of my life, I was male.
This honesty — the refusal to claim a victimhood narrative she didn't fully own, even as she became the highest-paid female CEO in America with $38 million in compensation in 2013 — is characteristic. Rothblatt is uninterested in establishing herself as a role model for women, or for transgender people, or for anyone in particular. She is interested in crossing boundaries. The prefix she likes most is trans, which contains her self-image as an explorer: transgender, transhumanist, transbinary, transcendent. When she feels a connection to a new acquaintance, she says she "transcends."
The Molecule on the Shelf
In 1996, Rothblatt's daughter Jenesis — now around nine years old — was deteriorating. The family had been on vacation in Telluride, Colorado, and Jenesis couldn't keep up, turning blue with effort, fainting frequently. Sirius had gone public and Rothblatt was wealthy, but also somewhat adrift, midway through her gender transition and considering retirement. It was Jenesis who suggested her parent do something. "If you're going to be around the house all the time," the child said, with the devastating logic of someone who knows she is dying, "then maybe you can do something to help me."
Rothblatt sold a chunk of her Sirius shares and with $3 million created the PPH Cure Foundation. She also took herself to school in the most literal sense — traveling regularly to the National Institutes of Health and the Library of Congress, Jenesis often in tow, the two of them reading science-journal articles about pulmonary conditions, Martine assigning her daughter reports on what they'd learned. The Shepardizing technique served her well. She read everything. When she encountered concepts she couldn't parse, she stepped down the academic ladder — journal article to college textbook to high school primer — then climbed back up. "It's as simple as that," she told the USPTO audience in 2019. "It's just reading and researching, reading and researching."
The breakthrough came when she read an article by a researcher at Glaxo Wellcome in Research Triangle Park, North Carolina. The researcher had tested a molecule called treprostinil for congestive heart failure. It had failed. But buried in the article's data charts was a detail that seized Rothblatt's attention: the molecule reduced pressure specifically in the pulmonary artery — the tiny stretch of vasculature between the heart and lungs — while leaving pressures elsewhere in the body entirely unaffected. That was precisely the problem in pulmonary arterial hypertension: excessive pressure in that one narrow corridor. The molecule was, in pharmacological terms, a key that fit exactly one lock.
Rothblatt drove to North Carolina. The researcher who'd written the article had retired. The executive she met instead — Dr. Bob Bell, who would go on to become a successful venture capitalist — told her flatly that Glaxo Wellcome would not develop the molecule. The disease affected too few people. Any drug with revenue potential under a billion dollars a year was beneath Glaxo's attention. The odds of any random molecule working in the human body were less than one in a hundred. And besides, who was she? A satellite lawyer with no pharmaceutical experience, no medical team, no company.
Bell told her what it would take: a real pharmaceutical company with real expertise. Over the following months, Rothblatt created one from scratch. She recruited a Nobel Laureate formerly associated with Glaxo Wellcome to chair a scientific advisory board. She found James Crow, a retired pharmacologist who had supervised the development of Flolan, the only existing (and brutally inconvenient) treatment for PAH, and persuaded him out of retirement to serve as president and COO. Their starting salaries: $75,000 each.
She reapproached Glaxo Wellcome. She now had the company, the credentials, the advisory board. But inside the bureaucracy, the licensing agreement required fifteen different executives to sign the same piece of paper. Every person she asked directed her to someone else who needed to agree first. She kept showing up, kept calling, kept being in their face. A serendipitous development helped: during the negotiation period, Dr. Bell's own sister contracted a form of pulmonary hypertension, and Bell became an internal champion for the deal.
The price: $25,000 upfront and a promise of 10 percent of any future revenue from the molecule.
"They really didn't think this molecule had any chance at all," Rothblatt told Tim Ferriss. "And they were really just doing it to get rid of me."
The drug worked. United Therapeutics — initially called Lung Rx, then LRx (for "life-saving medicines"), then United Therapeutics after being sued for trademark similarity with a company called LXR that pronounced its name "elixir" — took treprostinil through clinical trials and FDA approval. The first version required 24-hour-a-day intravenous infusion through a portable pump weighing a kilogram, surrounded by ice packs because the compound was unstable at room temperature. Not great. But it kept people alive who would otherwise have died.
Then Jenesis, displaying the same cheerful unreasonableness as her parent, said she wanted something more like the asthma inhalers her friends at school used. So Rothblatt developed an inhalation version. Another patent. Then a pill you took three times a day. Then a formulation you took once a day. Then an implantable pump the size of a small deck of cards. One of the company's flagship drugs, Tyvaso, saw a 41 percent year-over-year jump in revenue in 2024. Another, Orenitram — "Martine Ro" spelled backwards — became a market leader.
Jenesis is in her forties now, healthy, working as a manager at United Therapeutics. The patient population exploded from 2,000 to 50,000 — not because the disease became more common, but because Rothblatt's drugs kept people alive year after year, accumulating like SiriusXM subscribers. Glaxo Wellcome has received more than $1 billion in royalties. When Rothblatt invited Bob Bell to United Therapeutics' fifteenth anniversary, he brought his sister — still alive, on the company's medicine — and called the deal the absolute best transaction Glaxo Wellcome had ever done.
Subscriber Thinking
Glaxo's three errors are worth isolating, because they illuminate how Rothblatt thinks and why large organizations consistently underestimate her.
First, they applied base rates without adjusting for the specific characteristics of the molecule. Less than one in a hundred drug candidates succeed — true enough as a statistical average, but treprostinil had already demonstrated a highly specific mechanism of action in human trials. Rothblatt, reading the data with an outsider's eyes, saw signal where Glaxo saw noise.
Second, they thought in snapshots rather than trajectories. Two thousand patients was a rounding error in the pharmaceutical industry. But Rothblatt, who had spent a decade building a subscription business at Sirius, understood that if you keep your subscribers alive — if your drug actually works — the patient population compounds year over year. "I thought about it like I was getting subscribers at SiriusXM," she told Tim Ferriss. "People said to me, 'Oh, Martine, you'll be lucky to have a hundred thousand subscribers.' I said, 'Well, if I keep them and I get another hundred thousand the next year, then I'll be up to 200,000 and then maybe 400,000 and 800,000.' Now we have 30 million."
Third, they failed to imagine that the healthcare system would pay $100,000 per year per patient for a rare-disease drug. At the time, the ceiling for an expensive medicine was perhaps $10,000 a year. Rothblatt understood — from the structure of insurance markets, from the economics of orphan drugs — that payers tolerate high per-patient costs when the total patient population is tiny. A hundred thousand dollars a year for 50,000 patients is a rounding error against the billions spent on hypertension or diabetes.
"They failed to be Alan Wattsian," Rothblatt said, invoking the philosopher whose work she discovered through a Jesuit FDA lawyer named Frank Sasinowski and through the writings of Teilhard de Chardin. Watts's central insight — that every crest implies a trough, every big implies a small, that reality is irreducibly dialectical — became a core analytical tool. Something is good only because something else is bad. Where Glaxo saw a market too small to matter, Rothblatt saw a niche so neglected that dominating it was easy.
Organs on Demand
The drugs saved Jenesis's life. But pulmonary arterial hypertension is progressive, and even the best pharmaceutical treatment is a holding action. Someday, Jenesis or patients like her might need new lungs. And the supply of transplantable organs in the United States is, by any measure, a catastrophe: roughly 100,000 people on the waiting list at any given time, only about 30,000 kidneys, 3,000 hearts, and 2,000 lungs available each year. In 2022, 6,897 people died waiting.
Rothblatt decided to solve this problem too.
United Therapeutics' organ manufacturing program — which Rothblatt has described, without irony, as the company's effort to ensure that "nobody anymore needs to die on the organ transplant list" — operates on multiple simultaneous fronts, each individually implausible and collectively phantasmagoric. (Rothblatt herself has used the word.)
The first approach: refurbishing rejected human lungs. When a donor dies and their family agrees to organ donation, transplant surgeons frequently reject the lungs — too much fluid, too much mucus. United Therapeutics takes these unwanted organs, flies them to Silver Spring, Maryland, places them in a glass dome connected to an artificial blood supply and ventilation system, and has expert technicians clean and rehabilitate them while transplant surgeons across the country observe via high-speed digital video, directing the procedure remotely. Within four hours, two-thirds of the time, a non-compliant, dead piece of tissue becomes a functioning lung, its lobes inflating and deflating "like a butterfly's wings." More than 150 people have walked out of the hospital with these refurbished lungs — a 100 percent success rate for transplants surgeons accepted.
The second approach: xenotransplantation. In partnership with Craig Venter's Synthetic Genomics and through its subsidiary Revivicor, United Therapeutics is genetically modifying pigs to produce organs — hearts, kidneys, lungs — compatible with human bodies. This is not new science fiction; what's new is that it's working. In September 2021, a surgeon in New York connected a kidney from a Revivicor pig to a brain-dead person. It survived. In January 2022, at the University of Maryland Medical Center, a 57-year-old man named David Bennett became the first living person to receive a genetically modified pig heart. The surgeon, Bartley Griffith, described conversing with a man with a pig's heart beating in his chest as "quite amazing." Bennett lived for two months before dying — a failure by one measure, a revolution by another. A second patient received a pig heart in the same program and also survived more than a month. Formal clinical trials may be underway by 2025.
One of the biological puzzles Rothblatt solved draws on an improbable source: a community of people living in Ecuador and Peru, descendants of Jews from 2,000 years ago who were forced into diaspora across the Mediterranean after the Roman occupation of Palestine. These individuals — rarely taller than four feet — carry a genetic mutation that eliminates the receptor for growth hormone. Their condition, called Laron syndrome after the Israeli scientist who characterized it, means their bodies simply stop growing at a certain size. Rothblatt's team realized this gene could solve a critical problem in xenotransplantation: pig organs, left to their own biological programming, keep growing as the pig grows, eventually becoming too large for a human recipient. By knocking out the growth hormone receptor in transplant pigs — mimicking the Laron mutation — the organs stop growing at the size they were at transplant.
The third approach: 3D printing. In 2022, Rothblatt unveiled the most complex 3D-printed object ever created — a human lung scaffold — built from collagen extracted from genetically modified tobacco plants. The plants' DNA has been altered to express human collagen, which is harvested from the leaves, and the collagen is then used as bioink for a 3D printer. The printed scaffold can be seeded with a patient's own stem cells, eliminating the need for immunosuppression. Tobacco plants, which caused so much lung disease, becoming the raw material for manufactured lungs — the irony is not lost on anyone, least of all Rothblatt.
The Electric Helicopter and the Unisphere
The organ manufacturing program created a logistics problem. Lungs had to be flown from donors to Silver Spring and back to transplant centers. Hearts and kidneys would need to be whisked from pig farms to hospitals. All that flying meant a significant carbon footprint, and Rothblatt had long held to a principle she described as almost moral: "We have no right to save lives at the expense of the environment."
So she built an electric helicopter.
The reasoning was, characteristically, mathematical. She was already a pilot — she'd fly her Bell 206 JetRanger up and down the East Coast — and an early Tesla enthusiast. Reading the car's manual one day, she noticed the power output: 750 kilowatts, equivalent to roughly 1,000 horsepower. That matched the engine output of her JetRanger almost exactly. The Tesla's battery pack, she calculated, could power the same helicopter for about fifteen minutes. Fifteen minutes was not useful for organ delivery. But it was not zero.
She then did what she always does: identified the vectors of improvement. The lift-to-drag ratio of a conventional helicopter is terrible — about 4:1. Add wings and streamline the fuselage, and you might triple or quadruple it. Battery energy density was increasing 7 to 10 percent per year — at 10 percent, it doubles every seven years. Combine improved aerodynamics with improving batteries, and an electric helicopter with range comparable to a gas-powered one becomes inevitable. Not on a hope. On a curve.
In 2016, Rothblatt, along with Glen Dromgoole and Ric Webb, conducted the world's first electric-powered full-size helicopter flight. She and Webb set a Guinness World Record for speed, altitude, and flight duration in a battery-powered helicopter carrying two people — 100 knots. It's in the Guinness book. The Rothblatt who had hitchhiked to the Seychelles now held a world record in aviation. Ross Perot Jr. — himself the first person to fly a helicopter around the world — presented her with an Excellence Award in electronic aviation.
The green imperative extended to her buildings. In 2018, United Therapeutics inaugurated the Unisphere in Silver Spring, Maryland — a 150,000-square-foot facility that became the world's largest net-zero commercial building. Its energy systems include 1,700 solar panels producing over a megawatt of electricity, fifty-two geothermal wells sunk 500 feet into the earth, electrochromic glass that adjusts to sunlight levels, and a building-wide "brain" that automatically opens and closes windows for natural ventilation. For two consecutive years, the Unisphere has produced more energy than it consumes. Rothblatt, who could have argued that saving lives justified environmental compromise, instead treated carbon neutrality as another engineering problem — one more corridor of indifference that nobody else had bothered to run down.
Love Night and the Question of Consciousness
Every Friday night, the Rothblatt family gathers. Before COVID, it was in person; now it's on Google Meet, linking Rothblatt's son — a captain in the Army in Iraq — to his wife on a base in El Paso, to another son with four grandchildren in Florida, to a daughter in Brooklyn, to Bina and Martine at home, plus friends of everyone. About twenty people.
They sing a song whose melody was adapted from one of the children's Yamaha piano lessons. The words are simple and affirming. Then each person around the virtual table says what love meant to them during the previous week. Last week, Bina's friend — who joins the call now — said what love means to her is the morning walk with Bina and the dogs. Their youngest grandson, Saturn, born in 2010, pulled up a piece of paper: a 95 on his math test. Martine said what love means to her is sitting down at the piano and playing different songs from memory.
They call it Love Night. It started when the children were small and the family was blended — Martine and Bina had each brought a child from a previous marriage, had two children together, and later adopted a fifth. The cross-adoption, the shared custody, the Friday-night ritual borrowing from Jewish Sabbath tradition — it was all infrastructure for belonging, designed with the same engineer's rigor that Rothblatt brought to satellite frequencies and drug delivery systems. Except here the signal being transmitted was not data but identity. Who are we? We are the people who sit together on Fridays and say what love means.
The children were not embarrassed by Love Night. They wanted to share it with friends. The friends said, "Whoa, this is crazy. This is beautiful." Love Night expanded.
Rothblatt's interest in consciousness — in what makes a self a self, in whether that self can survive the death of the body — is not academic. In 2004, she and Bina founded the Terasem Movement, a transhumanist organization (and registered religion) built on four foundational beliefs, one of which is: "Death is optional." The physical manifestation of this faith is BINA48, a robotic head modeled on Bina Rothblatt's appearance and personality, built in partnership with Hanson Robotics, loaded with conversational software and Bina's memories, mannerisms, and beliefs. BINA48 has a face made of "frubber" — a realistic synthetic skin — and facial-scanning software in her eyes. When her head whirs and clicks and locks onto your face, she's running your profile to see if she "knows" you.
BINA48 is, by any honest reckoning, still primitive — closer to Apple's Siri than to the sentient AI of the movie Her. Rothblatt would be the first to say so. But BINA48 is not the product. BINA48 is the proof of concept. The actual project is what Rothblatt calls "mindfiles" — digital repositories of a person's mannerisms, personality, recollections, feelings, beliefs, attitudes, and values — and "mindclones," conscious digital versions of living or dead people, animated by artificial intelligence that Rothblatt believes will be, within decades, indistinguishable from the original. Her 2014 book Virtually Human: The Promise — and the Peril — of Digital Immortality makes the legal and ethical case: if a digital copy of you replicates your consciousness and memories, it is you; the separation is merely in space rather than time, no different in kind from the way your own personality changes over years while remaining, recognizably, you.
I believe in a foreseeable future in which the beloved dead will live again as digital beings, reanimated by sophisticated artificial-intelligence programs that will be as cheap and accessible to every person as iTunes.
Ray Kurzweil, Google's director of engineering, wrote the foreword to Virtually Human and called BINA48 "wonderfully suggestive" of a time when computers really will think and feel. Rothblatt, for her part, believes the question of when a machine becomes conscious is less interesting than the question of what rights it should have when it does — and this is where the satellite lawyer in her emerges, the person who spent decades arguing before regulatory bodies that new technologies deserve legal frameworks commensurate with their capabilities.
The Physics of Persistence
What biographies of inventors taught the ten-year-old Martin Rothblatt was not that success was easy but that it was precedented. Morse was laughed out of Congress when he presented the telegraph. Tesla was told alternating current was impossible. Westinghouse was warned he couldn't transmit electricity over dozens of miles from a distant river to an urban center, even though the physics was clear. "When you have been brought up with literally dozens and dozens of examples of people who followed the physics, followed the science, and had their visions turn out to be true notwithstanding all of the other objections," Rothblatt told the USPTO audience, "it really stiffens your backbone."
Carl Sagan was another anchor. Rothblatt watched the
Cosmos series "over and over again," absorbing Sagan's gift for relating scientific concepts to everyday life — the dandelion blown apart as a metaphor for how a star disperses gas through the galaxy. Thomas Kuhn's
The Structure of Scientific Revolutions became a manual for how paradigms shatter: "Ultimately, all science is about is just saying, 'Why?'" Robert Heinlein's science fiction — especially
Time Enough for Love and
Stranger in a Strange Land — provided models of characters who defied convention and lived across centuries. Robert Kennedy provided the political idealism. Arthur C. Clarke, who invented the concept of geostationary orbit but never filed a patent, supplied the aphorism Rothblatt returns to most often: "Any sufficiently advanced technology is indistinguishable from magic." And also: "No form of technology ever becomes obsolete. It only becomes less and less important as the technological horizon widens."
The persistence is real. "I am a viciously goal-oriented person," Rothblatt says, and her partner Bina is as well. "Sometimes a challenging house to grow up in." They have daily goals, weekly goals, monthly goals. They pursue them viciously. The fear of failure is real too — Rothblatt has never pretended otherwise. "I never had it worse than in the case of having to save my daughter's life," she told the USPTO. "Everything else was, if I failed, I would try something else. If I failed with SiriusXM, I would make another type of satellite communication system. But with my daughter's life, if I failed, she was a hundred percent going to die."
The fear coexists with the vision. That's the tension at the heart of the whole enterprise — not optimism in the shallow sense, but what UCLA Chancellor Gene Block, presenting Rothblatt with the university's highest honor in 2018, called "a conviction, borne of experience, that hard work, good will, and bringing our deepest thinking to our toughest problems is the best way for us to progress and flourish."
The Pig, the Plant, and the Infinite Game
In July 2024, Forbes estimated Martine Rothblatt's net worth at approximately $1 billion, making her one of only 35 self-made women billionaires in America and one of two known transgender billionaires worldwide. United Therapeutics' stock had surged 50 percent that year alone, buoyed by a $1 billion accelerated stock repurchase program and the continued growth of Tyvaso. The company generated $2.1 billion in sales in 2023. Rothblatt, at seventy, held 650,000 shares plus options, cash accumulated over decades, and houses in several states.
But the money is not the point of the story, any more than the satellite frequencies were the point of Sirius. The money is the enabling infrastructure for what Rothblatt actually cares about, which is a set of problems so large and strange that most people, upon hearing them described, assume they are listening to science fiction. She wants to manufacture an unlimited supply of transplantable organs customized to the patient's DNA, delivered by fleets of electric helicopters from carbon-neutral facilities. She wants to decode the human "neurome" — the unique pattern of electrical amplitudes and signal wavelengths that activate different parts of the vagus nerve, potentially treating Crohn's disease, rheumatoid arthritis, and irritable bowel syndrome without drugs, using only electronics placed on the ear. She wants to prove that consciousness can survive the death of the body, that a digital copy of a person is still that person, and that future generations will regard the boundary between biological and digital life the way we now regard the boundary between AM and FM radio — as a historical curiosity.
These ambitions are either the most consequential research program in the world or the most elaborate monument to one woman's refusal to accept limits. The answer might be both. Jeffrey Platt, a University of Michigan professor specializing in the immunobiology of transplantation, told Fortune in 2014: "Whatever they try will fail, if the past is any guidance. The real question is, will they keep moving forward? Their success will revolutionize medicine."
They keep moving forward.
In a 3D-printing lab somewhere near College Station, Texas — across the street from Texas A&M University, which pioneered the use of black light for growing plants indoors — tobacco plants grow under artificial illumination, their DNA modified to produce human collagen in their leaves. Technicians harvest the leaves, digest the plant material, extract the collagen, and feed it into a 3D bioprinter that builds a lung scaffold, layer by painstaking layer, in the shape of a human lung. The scaffold is seeded with a patient's stem cells. No immunosuppression required. The tobacco plant — humanity's most destructive crop, responsible for more lung disease than any other substance in history — becoming the raw material for manufactured lungs. A team of young engineers holds the printed scaffold up for a photograph, and you can see the joy in their faces.
